Investment Rating - The investment rating for the company is "Outperform the Market" [5] Core Insights - The company is expected to achieve significant growth in both profit and value by the end of 2025, with projected revenue of 615.68 billion yuan, a year-on-year increase of 16.5%, and a net profit of 154.08 billion yuan, reflecting a 44.1% growth [1] - The New Business Value (NBV) has shown strong growth, reaching 45.75 billion yuan in 2025, a substantial increase of 35.7%, marking the highest growth rate since 2017 [2] - The company has significantly increased its equity asset allocation, with the proportion of stocks and funds rising from 12.18% at the end of 2024 to 16.89% by the end of 2025, leading to a total investment return rate of 6.09%, up by 59 basis points year-on-year [3] Financial Performance and Forecast - The company forecasts revenue growth from 528.57 billion yuan in 2024 to 615.68 billion yuan in 2025, with a projected net profit increase from 106.94 billion yuan to 154.08 billion yuan during the same period [4] - The diluted earnings per share (EPS) are expected to rise from 5.45 yuan in 2025 to 6.87 yuan by 2028, with corresponding price-to-earnings (P/E) ratios decreasing from 7.21 to 5.72 [6]
中国人寿:价值与利润高增,权益投资占比提升-20260326